Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of dapagliflozin versus placebo in type 2 diabetes mellitus with inadequately controlled hypertension on ACE inhibitor or angiotensin receptor blocker therapy
2010-019798-13Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and hypertension (HTN) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Change from baseline in seated systolic blood pressure at Week 12 and Change from baseline in HbA1c at Week 12. Started Oct 2010; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on 2010-019798-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019798-13.